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Bronchiectasis Is a Model for Chronic Bacterial Infection
Inducing Autoimmunity in Rheumatoid Arthritis
Anne-Marie Quirke,1 Elizabeth Perry,2 Alison Cartwright,1 Clive Kelly,3 Anthony De Soyza,4
Paul Eggleton,5 David Hutchinson,6 and Patrick J. Venables1
Objective. To examine the potential of chronic se-
vere bacterial infection to generate rheumatoid factor (RF)
and anti–citrullinated protein antibodies (ACPAs), by
studying patients with bronchiectasis (BR) alone and BR
patients with rheumatoid arthritis (BR/RA).
Methods. We studied 122 patients with BR alone,
50 patients with BR/RA, and 50 RA patients without lung
disease, as well as 87 patients with asthma and 79 healthy
subjects as controls. RF levels were measured using an
automated analyzer, and cyclic citrullinated peptide 2
(CCP-2) was used to detect ACPAs. The fine specificities
of citrullinated a-enolase peptide 1 (CEP-1), Cit-
vimentin, and Cit-fibrinogen to their arginine-containing
control peptides (arginine-containing a-enolase peptide 1
[REP-1], vimentin, and fibrinogen) were measured by
enzyme-linked immunosorbent assay.
Results. Among the BR patients and control sub-
jects, 39% and 42%, respectively, were ever-smokers. The
frequency of RF positivity in serum was increased in BR
patients compared with controls (25% versus 10%), as
were the frequencies of antibodies to CCP-2 (5% versus
0%), CEP-1 (7% versus 4%), Cit-vimentin (7% versus
4%), and Cit-fibrinogen (12% versus 4%), although only
the differences for RF and Cit-fibrinogen were signifi-
cant (P < 0.05). We observed a corresponding increase in
the frequency of antibodies to the arginine-containing
control peptides in BR patients compared with controls
(for REP-1, 19% versus 4% [P < 0.01]; for vimentin, 16%
versus 4% [P < 0.05]), demonstrating that the ACPA re-
sponse in patients with BR is not citrulline specific. The
lack of citrulline specificity was further confirmed by ab-
sorption studies. In BR/RA patients, all ACPA responses
were highly citrulline specific.
Conclusion. Bronchiectasis is an unusual but po-
tent model for the induction of autoimmunity in RA by
bacterial infection in the lung. Our study suggests that
the ACPA response is not citrulline specific during the
early stages of tolerance breakdown but becomes more
specific in patients with BR in whom BR/RA develops.
Rheumatoid arthritis (RA) is an autoimmune dis-
ease characterized by the presence of disease-specific anti–
citrullinated protein antibodies (ACPAs) (1). Because
ACPAs can be detected in patients with RA several years
before the diagnosis is made (2), it is now thought that RA-
related autoimmunity may be initiated outside the joint, in
sites such as the lungs and the periodontium (3,4).
Smoking is a known risk factor for RA (3,5). There
is accumulating evidence that the ACPA response results
from smoking-induced inflammation of the lung, result-
ing in increased expression of citrullinated proteins (6,7).
Periodontitis, which often is cited as one of the most com-
mon inflammatory diseases, is also a risk factor for RA (8),
and patients with periodontitis have increased levels of anti-
bodies against the uncitrullinated forms of RA autoanti-
gens (9,10).
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Bronchiectasis (BR) has been recognized as a risk
factor for RA since publication of the classic studies by
Walker nearly 50 years ago (11). He observed that among
516 patients with RA, 2.5% had symptoms of antecedent
BR compared with 0.3% of 300 patients with degenerative
joint disease. Similar findings have been observed in other
cohorts of patients with RA (12). Importantly, in a more
recent study, RA developed in 2 patients with BR over
12 months of followup (13). Although it would be difficult
to confidently calculate the relative risk in these studies, it
would be fair to conclude that BR is a potent risk factor
for RA in a minority of patients. Similar to other severe
chronic bacterial infections, BR has been known for dec-
ades to be associated with a high frequency of rheumatoid
factors (RFs) (14,15), suggesting that chronic bacterial
infection of the lung could lead to autoimmunity in RA.
However, there are no published studies of the fine speci-
ficity of ACPAs in BR, and the potential mechanisms of
citrulline-specific autoimmunity induced by bacterial
infection have not been studied in BR.
In this study, we used BR as a model to study the
evolution of the ACPA response induced by severe chronic
bacterial infection, as 2 cross-sectional “snapshots” at the
beginning and the end of development of the ACPA re-
sponse, in patients with BR and BR patients in whom RA
later develops. To assess whether BR could be a model for
the induction of autoimmunity in RA, we measured the lev-
els of autoantibodies to both citrullinated and uncitrul-
linated peptides in a well-documented group of BR
patients without RA, using healthy subjects and patients
with asthma as controls. To examine the ACPA response in
patients with established disease, we measured the levels of
these autoantibodies in BR patients with concomitant RA
(BR/RA) and in RA patients without any lung disease.
PATIENTS AND METHODS
Serum samples from patients and control subjects. Se-
rum samples from 122 patients with BR, 50 patients with BR/RA,
50 RA patients without lung disease, 87 patients with asthma,
and 79 healthy control subjects were obtained from several
centers across the UK (13). All of the patients with BR were
adults (age .18 years) with high-resolution computed tomog-
raphy (HRCT)–proven symptomatic non–cystic fibrosis BR
and a history of $2 respiratory infections per year. HRCT was
performed by chest radiologists who were not involved in the
study, and all patients in the BR cohorts were receiving fol-
lowup care from a respiratory consultant (a physician with an
interest in BR). Patients with coexistent intestinal lung disease,
asthma, emphysema, allergic bronchopulmonary aspergillosis,
a history of or current tuberculosis, or those in whom any
other lung disease was observed by HRCT or reported in
respiratory clinic notes (referencing electronic letters and
patients’ paper notes taken at the respiratory clinic) were
excluded from the study. All BR patients also underwent a
musculoskeletal examination by a rheumatologist and were
excluded if they had a history of inflammatory joint pain,
inflammatory arthritis, or any synovitis (13). All RA patients
met the American College of Rheumatology/European League
Against Rheumatism 2010 criteria for RA (16). RF was present
in significantly greater numbers of BR/RA patients compared
with patients with RA alone (13). Multicenter ethics approval
was obtained at all participating centers (Integrated Research
Application System approval no. 12324). Recruitment was per-
formed between May 2012 and May 2013.
Antibody measurements. The levels of IgM RFs were
measured with an Hitachi Modular P analyzer and were defined
as positive or negative according to the cutoff levels recom-
mended by the manufacturer. All of the ACPA tests were per-
formed in the same laboratory by a single investigator (A-MQ).
Anti–cyclic citrullinated peptide 2 (anti–CCP-2) antibody levels
were measured using a commercial enzyme-linked immunosor-
bent assay (ELISA) (Diastat; Eurodiagnostica) according to the
instructions of the manufacturer. Antibodies to immunodomi-
nant peptides from 3 established RA autoantigens, citrullinated
a-enolase peptide 1 (CEP-1; amino acids [aa] 4–21 [KIHA-cit-
EIFDS-cit-GNPTVE]) (17), Cit-vimentin (aa 59–74 [VYAT-
cit-SSAV-cit-L-cit-SSVP]), and Cit-fibrinogen b-chain (aa
36–52 [NEEGFFSA-cit-GHRPLDKK]) (10) were also meas-
ured by in-house ELISAs, as previously described (10). For all
assays, arginine-containing control peptides were run in paral-
lel. For the immunodominant peptides and control peptides, we
calculated the cutoff for positivity as the ninety-fifth percentile
of the value for normal controls, and all serum samples with val-
ues above this cutoff were considered positive. A standard curve
was included in all plates coated with citrullinated peptides and
those coated with uncitrullinated vimentin, and results were
expressed as arbitrary units. For assays without standard curves,
the results were expressed as the optical density (OD).
Inhibition/competition assays. Inhibition/competition
experiments were performed in the liquid phase. Six anti–
arginine-containing a-enolase peptide 1 (anti–REP-1)–positive
serum samples from patients with BR and 6 anti–CEP-1–
positive samples from patients with BR/RA were chosen. Sera
were incubated for 2 hours at room temperature and overnight
at 48C in buffer alone as control or in 1 mg/ml of either REP-1
or CEP-1. The mixtures were centrifuged at 16,200g for 20
Table 1. Demographic characteristics of the healthy control subjects
and patients*
n
Age, median
(IQR) years
Female
sex, %
Ever-smoker,
%
Healthy controls 79 60 (17) 74 42
Patients
Asthma 87 50 (27) 79 43
BR 122 66 (13) 65 39
BR/RA 50 68 (12) 72 42
RA 50 66 (15) 72 56
* There were no significant differences in age between patients with
bronchiectasis (BR), BR patients with rheumatoid arthritis (BR/RA),
and patients with RA. Patients with asthma were significantly younger
than subjects in all other groups. Healthy control subjects were signifi-
cantly younger then patients in the BR/RA and RA groups. There were
no significant differences in sex or smoking status between all groups,
with the exception of the group with asthma, in which the percentage of
female patients was significantly higher than that in the group with BR.
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minutes, the BR supernatants were transferred to REP-1–
coated plates and the BR/RA supernatants were transferred to
CEP-1–coated plates, and assays were performed as described
above. All results were expressed as the OD at 450 nm.
Statistical analysis. The Mann-Whitney nonparamet-
ric test (for unmatched groups) was used to compare differences
between antibody responses in the cohorts of serum samples.
Spearman’s nonparametric correlations between data sets were
assessed. Calculations were performed using GraphPad software.
RESULTS
Demographic characteristics of the study partici-
pants. The demographic characteristics of the patients
and control subjects are shown in Table 1. The patients
were well matched for sex, with a preponderance of wo-
men in all groups, although the median age of subjects in
the control group was ;7 years younger than that of
patients with BR, patients with BR/RA, and patients with
RA. Ever-smoking was reported by 39% of the BR pa-
tients without RA, 42% of the control subjects, 43% of the
patients with asthma, and 56% of the patients with RA
only. The frequency of RF was significantly increased in
patients with BR (25%) compared with healthy controls
(10%), as previously observed (14,15). As expected, highly
significant increases in RF positivity were observed in both
the RA group and the BR/RA group compared with con-
trols (Table 2).
Non–citrulline-specific ACPAs in BR patients with-
out RA. Six of the BR patients (5%) were anti–CCP-2
antibody positive. Although the rates of anti–CCP-2 posi-
tivity were not significantly different between BR patients
and controls (Table 2), the titers of anti–CCP-2 antibodies
in BR patients were significantly increased compared with
those in both healthy controls (P , 0.001) and patients
with asthma (P, 0.01) (Figure 1). The frequencies of anti-
body positivity to the “specific” citrullinated peptides were
slightly increased in patients with BR compared with con-
trols (for CEP-1, 7% versus 4%; for Cit-vimentin, 7% ver-
sus 4%; for Cit-fibrinogen, 12% versus 4%); only the
difference in the frequency of antibodies to Cit-fibrinogen
reached statistical significance (P, 0.05) (Table 2). When
comparing the titers of antibody binding, the levels of anti-
bodies to all 3 peptides were significantly increased in BR
patients compared with patients with asthma and, in the
case of both anti-vimentin and anti–Cit-fibrinogen, com-
pared with healthy controls (Figure 2).
The frequencies of antibodies to the arginine-
containing control peptides from the specific citrullinated
antigens were also increased in patients with BR com-
pared with healthy controls (for REP-1, 19% versus 4%;
for vimentin, 16% versus 4%; for fibrinogen, 9% versus
4%) (Table 2). In addition, the titers of anti–REP-1 and
anti-vimentin were significantly increased in patients with
BR compared with both healthy controls and patients with
asthma (Figure 2). The lack of citrulline-specific ACPA
responses in the BR patients was further suggested by the
strong correlations between antibodies to each of the cit-
rullinated peptides compared with their uncitrullinated
Table 2. Serum antibody positivity in the healthy control subjects and
patients*
Antibody
Healthy
controls
(n5 79)
Patients
Asthma
(n5 87)
BR
(n5 122)
BR/RA
(n5 50)
RA
(n5 50)
Rheumatoid factor 10 16 25† 82‡ 52‡
CCP-2 0 1 5 88‡ 48‡
CEP-1 4 1 7 60‡ 24§
Cit-vimentin 4 3 7 56‡ 20§
Cit-fibrinogen 4 0 12† 74‡ 40‡
REP-1 4 3 19§ 12 0
Vimentin 4 3 16† 20§ 2
Fibrinogen 4 2 9 6 8
* Values are the percent. BR5 bronchiectasis; BR/RA5BR with
rheumatoid arthritis (RA); CCP-25 cyclic citrullinated peptide 2; CEP-
15 citrullinated a-enolase peptide 1; REP-15 arginine-containing
a-enolase peptide 1.
† P , 0.05 versus controls, by Fisher’s exact test.
‡ P , 0.001 versus controls, by Fisher’s exact test.
§ P , 0.01 versus controls, by Fisher’s exact test.
Figure 1. Anti–cyclic citrullinated peptide 2 (anti–CCP-2) levels in
healthy control subjects, patients with asthma, patients with bron-
chiectasis (BR), BR patients with rheumatoid arthritis (BR/RA),
and patients with RA. Each symbol represents an individual subject;
horizontal lines show the median. NS5not significant. **5P ,
0.01; ***5P , 0.001; ****5P , 0.0001.
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Figure 2. Levels of anti–citrullinated a-enolase peptide 1 (anti–CEP-1) and anti–arginine-containing a-enolase peptide 1 (anti–REP-1) (A),
anti–Cit-vimentin (anti-cVim) and anti-vimentin (B), and anti–Cit-fibrinogen (anti-cFib) and anti-fibrinogen (C) in healthy control subjects,
patients with asthma, patients with BR, patients with BR/RA, and patients with RA. Each symbol represents an individual subject; horizontal
lines show the median. *5P , 0.05; **5P , 0.01; ***5P , 0.001; ****5P , 0.0001. See Figure 1 for other definitions.
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variants (for anti–CEP-1 versus anti–REP-1, r5 0.502
[P , 0.0001]; for anti–Cit-vimentin versus anti–vimentin,
r5 0.725 [P, 0.0001]; for anti–Cit-fibrinogen versus anti-
fibrinogen, r5 0.798 [P, 0.0001]) (Figure 3).
The citrulline specificity of the antibody response in
patients with BR was also examined by performing absorp-
tion experiments with the 2 enolase peptides, CEP-1 and
REP-1, in 6 of the serum samples from BR patients. The
anti–REP-1 response in these sera was absorbed partially
and almost equally with both REP-1 and CEP-1 (Figures
4A and B), suggesting that antibodies were cross-reactive
for both peptides and further confirming their lack of citrul-
line specificity.
Citrulline specificity and ACPA levels in patients
with BR/RA. Compared with the patients with BR, those
with BR/RA had a highly citrulline-specific ACPA response
to each antigen tested (Figures 1 and 2). In addition, no sig-
nificant correlations between the antibody responses to the
citrullinated peptides and the arginine-containing control
peptides were observed in patients with BR/RA, with the
exception of the correlation between anti–Cit-vimentin and
anti-vimentin (r5 0.455 [P, 0.0001]) (Figure 3).
Although the percentage of ever-smokers was
reduced among patients with BR/RA compared with that
among patients with RA alone (42% versus 56%; P5
0.06), the rate of seropositivity in BR/RA patients com-
pared with RA patients was significantly increased for
each ACPA tested: for anti–CCP-2, 88% versus 48%; for
anti–CEP-1, 60% versus 24%; for anti–Cit-vimentin, 56%
versus 20%; and for anti–Cit-fibrinogen, 74% versus 40%
(Table 2) (all P , 0.01). The citrulline specificity of the
ACPA response in patients with RA was confirmed by the
lack of correlation with the response to the arginine-
containing peptides (Figures 2 and 3) and by complete
absorption of the anti–CEP-1 response in 6 BR/RA serum
specimens only with the CEP-1 peptide (Figures 4C and
D). Taken together, these data showed that the citrulline
specificity of ACPAs in patients with BR/RA was in-
Figure 3. Correlations between the levels of antibodies to specific anti–citrullinated protein antibodies and their arginine-containing control pep-
tides in patients with BR, patients with BR/RA, and patients with RA. A, Anti–citrullinated a-enolase peptide 1 (anti–CEP-1) responses versus
anti–arginine-containing a-enolase peptide 1 (anti–REP-1) responses. B, Anti–Cit-vimentin (anti-cVim) responses versus anti-vimentin responses.
C, Anti–Cit-fibrinogen (anti-cFib) responses versus anti-fibrinogen responses. See Figure 1 for other definitions.
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creased compared with that in patients with BR alone,
and its magnitude was increased compared with that in
RA patients without any lung disease.
DISCUSSION
Our study showed significantly elevated levels of
ACPAs in patients with BR, although the antibody re-
sponse was not citrulline specific. We suggest that after
tolerance has been breached, subsequent long-term expo-
sure to citrullinated antigens in the inflamed lung results
in the spreading of epitopes recognized by B cells to cit-
rullinated peptides. Epitope spreading in patients with
BR in whom RA develops may well be reflected by the
markedly citrulline-specific responses to CCP-2, CEP-1,
Cit-fibrinogen, and Cit-vimentin observed in the BR/RA
patients. We also observed an increased frequency of RF
positivity in patients with BR, but this has been well
described in previous studies (14,15). Furthermore, RFs
can also be found in patients with other autoimmune and
nonautoimmune conditions, as well as in healthy individ-
uals (for review, see ref. 18). The increased titers and fre-
quencies of both ACPAs and RF in patients with BR/RA
compared with patients with RA may also reflect the
potency of BR in exacerbating the autoimmune response
in RA, once it has developed.
Our data suggest that this effect could not be
explained by cigarette smoking, which is a well-established
risk factor for RA. In our study the percentage of ever-
smokers was actually lower among BR patients compared
with controls, although it was increased slightly among the
RA patients without lung disease. However, these data
must be interpreted with caution, because “ever smoking”
is not regarded as a particularly robust measure of tobacco
exposure (19).
The largely arginine-specific autoantibody response
that we observed in patients with BR was remarkably simi-
lar to that observed in patients with periodontitis (10). This
pattern of response was also recently observed in a study by
Brink et al (20), in which antibodies against arginine-
containing peptides (including REP-1, vimentin [aa 60–75],
and fibrinogen b-chain [aa 36–52]) from RA autoantigens
were observed before the development of citrulline-specific
ACPAs in serum samples obtained from patients with RA
years before symptoms of RA developed. Importantly, that
study also included sequential samples. However, it was
entirely cross-sectional, and further prospective investiga-
tions will need to be carried out in BR patients at risk of
Figure 4. Antibody responses in anti–REP-1–seropositive patients with bronchiectasis (BR) and in anti–CEP-1–seropositive BR patients with
rheumatoid arthritis (BR/RA) in the presence of either REP-1 or CEP-1, as determined by enzyme-linked immunosorbent assay–based competition/
inhibition assays. A and B, Anti–REP-1 reactivity in the presence of REP-1 and CEP-1 in patients with BR. C and D, Anti–CEP-1 reactivity in the presence
of REP-1 and CEP-1 in patients with BR/RA. Each symbol represents a different patient; lines connect the individual data points. See Figure 2 for other
definitions.
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RA in order to confirm the evolution of the citrulline speci-
ficity of ACPAs in patients with BR in whom BR/RA sub-
sequently develops.
The results of the inhibition assay showed that in
BR patients the antibody response to the enolase peptides
CEP-1 and REP-1 not only is cross-reactive and lacking cit-
rulline specificity but also may be of low avidity, thereby
explaining the incomplete absorption of anti–REP-1 activ-
ity by the REP-1 peptide. Although we did not examine
antibody avidity in this study, a longitudinal study of
patients with presymptomatic RA showed that antibody
avidity gradually increased as the onset of joint disease
approached (21). Therefore, if certain bacterial infections
lead to the initiation of an ACPA response, our study and
others (9,10,20,21) suggest that infections such as periodon-
titis, BR, and others yet to be defined induce a low-titer,
low-avidity, non–citrulline-specific ACPA response in the
early phases of tolerance breakdown, which subsequently
evolves into the higher-avidity, higher-titer, and highly
citrulline-specific responses that characterize RA.
A limitation of this study is that the different
patient groups were selected from different regions of the
UK and were not matched for age. The large number of
BR/RA patients in our study does not reflect the preva-
lence of symptomatic BR in a random population of RA
patients, which is probably ;3% (11,12). The patients
with RA alone were also selected for this study based on
the absence of lung disease, and this bias may well reflect
the low prevalence of ACPAs in the RA group. However,
these results are entirely consistent with a meta-analysis
of several studies (22) and a recent large study, which
confirmed a strikingly low frequency (55%) of ACPAs in
230 RA patients without lung disease (23).
In contrast, the more heightened reactivity to cit-
rullinated antigens in patients with BR/RA could repre-
sent a certain type of disease in which reactivity to these
citrullinated antigens is dominant and perhaps related to
the airway disease. Demoruelle et al observed that 76% of
anti-CCP–positive subjects without arthritis had airway
abnormalities, including BR, and that articular RA devel-
oped in 2 of these subjects within a year (24), and Fischer
et al reported that 63% of patients with lung disease with-
out RA had “moderate to high” anti-CCP positivity (25).
Even though the current study cannot be regarded
as an epidemiologic study, we have demonstrated in this
substantial population of well-documented patients that
BR could be an unusual but potent model for the induc-
tion of autoimmunity in RA by bacterial infection in the
lung. To prove that this is a true causal relationship, lon-
gitudinal followup of patients with BR is required, and
such studies are under way within the UK Clinical
Research Network Study Portfolio.
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